68 Recruiting Carcinoma, Non-Small-Cell Lung Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Browse by Study Phase
Top Interventions for Carcinoma, Non-Small-Cell Lung
Related Conditions
Top Recruiting Carcinoma, Non-Small-Cell Lung Studies
MYLUNG Consortium Study Protocol 2
📍 Southern Cancer Center, PC — Daphne, Alabama
View Study & Checklist ➔A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
📍 Local Institution - 0221 — Des Moines, Iowa
View Study & Checklist ➔THIO Sequenced With Cemiplimab in Advanced NSCLC
📍 Central Alabama Research — Birmingham, Alabama
View Study & Checklist ➔A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
📍 City of Hope 2 — Duarte, California
View Study & Checklist ➔Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study
📍 Research Site — La Jolla, California
View Study & Checklist ➔A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
📍 UCLA Hematology/Oncology - Santa Monica — Los Angeles, California
View Study & Checklist ➔A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
📍 Local Institution - 0104 — Tampa, Florida
View Study & Checklist ➔Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
📍 Florida Cancer Specialists — Altamonte Springs, Florida
View Study & Checklist ➔A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
📍 Massachusetts General Hospital . — Boston, Massachusetts
View Study & Checklist ➔A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
📍 Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers — Chandler, Arizona
View Study & Checklist ➔A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
📍 Research Site — Beijing,
View Study & Checklist ➔Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
📍 Research Site — Tuscaloosa, Alabama
View Study & Checklist ➔A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
📍 Rush University Medical Center — Chicago, Illinois
View Study & Checklist ➔A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
📍 Holden Comprehensive Cancer Cener — Iowa City, Iowa
View Study & Checklist ➔Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
📍 Infirmary Cancer Care ( Site 0418) — Mobile, Alabama
View Study & Checklist ➔A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
📍 Research Site — Beverly Hills, California
View Study & Checklist ➔A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
📍 Alaska Oncology and Hematology, LLC — Anchorage, Alaska
View Study & Checklist ➔A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
📍 USC Norris Comprehensive Cancer Center — Los Angeles, California
View Study & Checklist ➔Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
📍 University of Alabama at Birmingham, Comprehensive Cancer Center — Birmingham, Alabama
View Study & Checklist ➔A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
📍 Oncocentro Serviços Médicos e Hospitalares Ltda — Fortaleza, Ceará
View Study & Checklist ➔Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
📍 Ironwood Cancer and Research Center — Chandler, Arizona
View Study & Checklist ➔A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
📍 City of Hope — Duarte, California
View Study & Checklist ➔Premedication to Reduce Amivantamab Associated Infusion Related Reactions
📍 Compassionate Cancer Care — Fountain Valley, California
View Study & Checklist ➔A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
📍 Arizona Oncology Associates, PC - HAL — Goodyear, Arizona
View Study & Checklist ➔A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
📍 City of Hope 1 — Newnan, Georgia
View Study & Checklist ➔A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
📍 Brookwood Medical Center — Birmingham, Alabama
View Study & Checklist ➔A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
📍 Southern Cancer Center, PC — Mobile, Alabama
View Study & Checklist ➔A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
📍 Research Site — Atlanta, Georgia
View Study & Checklist ➔Metabolic Response to Food in Lung Cancer
📍 Pennington Biomedical Research Center — Baton Rouge, Louisiana
View Study & Checklist ➔Osimertinib In EGFR Mutant Lung Cancer
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
View Study & Checklist ➔MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)
📍 Providence Oncology & Hematology Care Clinic - Eastside — Portland, Oregon
View Study & Checklist ➔A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
📍 Banner MD Anderson Cancer Center ( Site 0181) — Gilbert, Arizona
View Study & Checklist ➔A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
📍 Moores Cancer Center at UC San Diego Health — La Jolla, California
View Study & Checklist ➔A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
📍 University of Kentucky Chandler Medical Center ( Site 0019) — Lexington, Kentucky
View Study & Checklist ➔Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
📍 Lombardi Comprehensive Cancer Center, Georgetown University — Washington D.C., District of Columbia
View Study & Checklist ➔A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
📍 Alaska Oncology and Hematology — Anchorage, Alaska
View Study & Checklist ➔KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
📍 Banner MD Anderson Cancer Center ( Site 0001) — Gilbert, Arizona
View Study & Checklist ➔Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.
📍 University of Colorado Hospital — Aurora, Colorado
View Study & Checklist ➔